TB-500 and the strange afterlife of an actin-binding peptide.

The discovery story is small and unflattering. In 1981, Teresa Low and Allan Goldstein at George Washington University were grinding bovine thymus into protein fractions, looking for the immunological signal that explained why thymectomized mice failed. They found a 43-amino-acid peptide, sequenced it, named it thymosin β4, and assumed it was an immune messenger. They were wrong about the function and right about almost nothing else. A decade later, Daniel Safer and colleagues at the University of Pennsylvania identified what β4 actually does for a living: it sequesters G-actin. In a resting human neutrophil, roughly 70% of the monomeric actin pool is bound to thymosin β4. The 1981 paper had been about a thymic immune factor. The 1991 paper was about cytoskeletal mechanics. They were the same molecule.

From cytoskeletal accountant to wound-repair signal

TB-500 is the research peptide. It is a 17-amino-acid fragment of the parent molecule, encompassing residues 17–23 — the actin-binding LKKTETQ motif plus flanking sequence — and is what most labs use when they want to study β4's regenerative effects. The fragment retains the migration-promoting and angiogenic activity. The shorter sequence happens to also be the active site for hair-follicle stem-cell mobilization, identified by Philp and colleagues in a 2004 paper in Mechanisms of Development.

What thymosin β4 does outside the cell is harder to summarize. It promotes endothelial cell migration, accelerates re-epithelialization in dermal wounds, modulates the TGF-β1 and NF-κB signaling axes, and — here the literature gets more interesting than its reputation suggests — it appears to push macrophages toward a pro-resolution phenotype rather than simply suppressing them.

The 2024 Wayne State paper

The most consequential recent work comes from Gabriel Sosne's group at Wayne State University in Detroit, published in Frontiers in Immunology in October 2024. The team had previously shown that topical Tβ4, used as an adjunct to ciprofloxacin, improved outcomes in a Pseudomonas aeruginosa keratitis model. The mechanism was unclear. The 2024 paper proposes the answer: Tβ4 activates specialized pro-resolving mediator pathways and enhances macrophage efferocytosis, the process by which immune cells clear apoptotic debris before it can fuel a chronic inflammatory state.

Anti-inflammation closes a wound. Pro-resolution finishes the cleanup. The 2024 work suggests Tβ4 is doing the second job, not the first.

If that reframe holds in larger studies, it puts thymosin β4 in a different therapeutic category than steroids or NSAIDs. Resolution agonists let inflammation run its course and then accelerate the cleanup phase. The clinical implication is that Tβ4 should perform best in injuries where the resolution stage is what fails — corneal ulcers that won't close, diabetic wounds, indolent tendon injuries.

The cardiac story, and why it remains contested

In 2007, Nadia Smart, Paul Riley, and colleagues at University College London published in Nature a finding that, if true, would have made TB-500 the most consequential peptide of its decade: priming adult mouse hearts with thymosin β4 before infarction reactivated dormant epicardial progenitor cells, which migrated inward and contributed to neovascularization and — in their hands — new cardiomyocytes. A 2013 paper by Zhou and colleagues at Harvard, using lineage-tracing tools the original work lacked, concluded that adult epicardial cells did not become cardiomyocytes under β4 stimulation. The dispute is unresolved. What survives both interpretations is the angiogenic effect — Tβ4 reliably grows new vessels into ischemic tissue.

The non-obvious findings

First: a 2025 paper in Scientific Reports from a multi-institution group reports that Tβ4 stabilizes the blood-brain barrier under hypoxia through an S1PR1-dependent mechanism. Second: the hair-follicle work is more developed than the consumer literature acknowledges — Philp and colleagues demonstrated that the same residues 17–23 active in angiogenesis also activate follicular stem cells, with VEGF as the downstream effector. Third: in platelets, β4 controls the G-actin/F-actin equilibrium during thrombus formation, a function characterized in a 2022 Haematologica paper by Stark and colleagues at the University of Würzburg.

Often studied alongside

TB-500 appears most frequently in the literature paired with BPC-157, the gastric pentadecapeptide characterized by Predrag Sikiric's group at the University of Zagreb. The pairing is mechanistic, not arbitrary: BPC-157 acts primarily on the nitric-oxide and angiogenic axis with notable activity on tendon and ligament fibroblasts, while Tβ4 contributes the pro-resolution and migration components. The KLOW research blend (BPC-157, TB-500, GHK-Cu, KPV) reflects the same logic — four compounds with non-overlapping mechanisms in connective-tissue repair.